key: cord-0841294-2fgo8n01 authors: Merzon, Eugene; Green, Ilan; Shpigelman, Miriam; Vinker, Shlomo; Raz, Itamar; Golan‐Cohen, Avivit; Eldor, Roy title: Hemoglobin A1C is a Predictor of COVID‐19 Severity in Patients with Diabetes date: 2020-08-27 journal: Diabetes Metab Res Rev DOI: 10.1002/dmrr.3398 sha: e6b2399bd303a98d4a034c71d171655082142fd8 doc_id: 841294 cord_uid: 2fgo8n01 INTRODUCTION: Poor outcomes of coronavirus disease 2019 (COVID‐19) have been linked to diabetes but its relation to pre‐infection glycemic control is still unclear. METHODS: To address this question we report here the association between pre‐infection HemoglobinA1c (A1C) levels and COVID‐19 severity as assessed by need for hospitalization in a cohort of 2068 patients with diabetes tested for COVID‐19 in Leumit Health Services, Israel, between February 1 and April 30, 2020. Using the LHS integrated electronic medical records system we were able to collect a large amount of clinical information including age, sex, socioeconomic status, weight, height, body mass index, A1C, prior diagnosis of ischemic heart disease, depression/anxiety, schizophrenia, dementia, hypertension, cerebrovascular accident, congestive heart failure , smoking and chronic lung disease. RESULTS: Of the patients included in the cohort, 183 (8.85 %) were diagnosed with COVID‐19 and 46 were admitted to hospital. More hospitalized patients were female, came from higher socioeconomic background and had a higher baseline A1C. A prior diagnosis of cerebrovascular accident and chronic lung disease conferred an increased risk of hospitalization but not obesity or smoking status. In a multivariate analysis, controlling for multiple prior clinical conditions, the only parameter associated with a significantly increased risk for hospitalization was A1C≥9%. CONCLUSION: Using pre‐infection glycemic control data we identify A1C as a clear predictor of COVID‐19 severity. Pre‐infection risk stratification is crucial to successfully manage this disease, efficiently allocate resources and minimize the economic and social burden associated with an undiscriminating approach. This article is protected by copyright. All rights reserved. Poor outcomes of coronavirus disease 2019 (COVID -19) have been linked to diabetes [1] [2] [3] [4] but its relation to pre-infection glycemic control is still unclear. Glycemic levels during hospitalization have been linked to poor outcomes of COVID- 19 . In a study of 28 patients with COVID-19 and diabetes in Wuhan, China the Hemoglobin A1c (A1C) was similar between 14 patients who were admitted to the intensive care unit and those who were not [5] . In another study of 269 patients with severe disease upon hospitalization, hyperglycemia was not identified as associated with severity of disease upon admission but was associated with death [6] . In a retrospective study of 201 patients with COVID-19 pneumonia increased glucose levels were identified as a risk factor for the development of ARDS but not for death [7] . A similar observation was noted in a study of 85 patients hospitalized due to COVID-19admission glucose level was the strongest predictor of radiographic findings of ARDS [8] . In a large multicentered retrospective study including 7337 cases of COVID-19 of which 952 patients had type 2 diabetes (T2DM), mean glycemic levels between 70-180 mg/dL (3.9-10mmol/L) during hospitalization were found to predict lower mortality [9] . Despite this emerging evidence the relation between pre-infection glycemic control and COVID-19 severity is still unknown. To address this question we report here the association between pre-infection A1C levels and COVID-19 severity as assessed by need for hospitalization-in a cohort of 2068 patients with diabetes tested for COVID-19 in Leumit Health Services, Israel, between February 1 and April 30, 2020. This article is protected by copyright. All rights reserved. Leumit Health Services (LHS) is a large health maintenance organization in Israel, which provides services to around 730,000 members nationwide. The comprehensive LHS electronic medical records (LHS-EMR) system integrates medical, pharmaceutical and laboratory information and is continuously updated. Using the LHS-EMR we identified patients with a prior diagnosis of diabetes (based on the Israeli diabetes registry [10] ) who underwent at least one test for COVID-19 between 1 February and 30 April 2020. COVID-19 testing was done only by physician referral (based on clinical criteria of exposure to confirmed COVID-19 patients and/or symptoms suggesting COVID-19) using the Allplex TM 2019-nCoV Assay,(Seegene Inc., Seoul, Republic of Korea) until March 10th, 2020, and since then -the COBAS SARS-Cov-2 6800/8800 (Roche Pharmaceuticals, Switzerland) . Only patients with a positive COVID-19 test were considered as having COVID-19. Other information collected from LHS-EMR included age, sex, socioeconomic status (SES-defined according to the patients home address, using the Israeli Central Bureau of Statistics classification [11]), weight, height, body mass index (BMI), A1C, prior diagnosis of ischemic heart disease (IHD), depression/anxiety, schizophrenia, dementia, hypertension, cerebrovascular accident (CVA), congestive heart failure (CHF) , smoking and chronic lung disease. The validity of the diagnoses in the registry was previously examined and confirmed as high [12] . Among the selected population we identified patients who contracted COVID-19 and those who were hospitalized due to COVID-19. In Israel, most COVID-19 positive patients were treated as outpatients in what is referred to as home-hospitalization. This was done either in the patients' homes or converted hotels. Leumit health services homehospitalized patients received a pulse oxymeter and were followed twice daily by nurses via telemedicine or phone. Nurses were instructed to immediately refer a patient to a physician if his fever was ≥ 38C, blood oxygen saturation was ≤95% or shortness of breath developed. Hospitalization was at the discretion of the treating physician. The study protocol was approved by the Shamir Medical Center Review Board and the Research Committee of LHS . Statistical analysis was conducted using STATA 12 software (StataCorp LP, College Station, TX, USA). Assumptions were two sided with an α of 0.05. Initial analysis compared demographic characteristics between the patients with positive or negative Covid-19 tests, using Student's t-test and Fischer's exact χ2 test for continuous and categorical variables, respectively, based on normal distribution and variable characteristics. Categorical data are shown in counts and percentages. Data on continuous variables with normal distribution are presented as means with 95% confidence intervals (CI). Preliminary evaluation of risk estimates was conducted by stratified analyses. A1C was stratified as: <7%(53mmol/mol); 7-7.9% (53-62.8mmol/mol) ; 8-8.9% (63.9-73.8mmol/mol) or ≥9% (74.9mmol/mol) and obesity was defined as a BMI ≥ 30 Kg/cm 2 . Only patients who had at least one A1C test in the year prior to the COVID-19 test were included in the analysis. In patients who had more than one A1C measurement during the year prior to COVID-19 testing, the most recent measurement was used. Subsequently, multivariate logistic regression was used to estimate the odds ratios (OR) and 95% CI for the independent association between the following clinical characteristics -age, A1C ≥9% , sex, SES, smoking, IHD, depression/anxiety, schizophrenia, dementia, hypertension, CVA, CHF , smoking, chronic lung disease, obesity and COVID-19 disease severity has assessed by the need for hospitalization. This article is protected by copyright. All rights reserved. We identified 2,068 patients with diabetes who were tested for COVID-19 (ages 14 to 103 years) of which 183 (8.85 %) patients were diagnosed with the disease. In a primary univariate analysis, patients with COVID-19 were younger, more likely to be male, had a higher A1C and BMI, belonged to a lower SES and had fewer pre-existing medical conditions (Table 1) . Furthermore, amongst COVID-19 patients, more patients had an A1C≥9% (12.02% vs. 7.27%; p<0.05; crude OR of 1.84; 95% CI 1.13-2.99) ( Table 2 ). These differences may reflect infection "clusters" which were characteristic of the spread of COVID-19 in Israelthe major outbreak cluster was amongst the ultra-orthodox Jewish population which is characterized by a younger mean age (leading to fewer prior co-morbidities) and a lower SES. We conducted a complementary analysis amongst patients who were COVID-19 negative. Patients who were found negative to COVID-19 but with an A1C≥9% were younger [mean age-59.9 (95% CI 57. 5 Of the 183 patients with COVID-19, 46 were admitted to hospital. The mean A1C in hospitalized patients was higher than patients who were not hospitalized. More hospitalized patients had an A1C between 8-8.9% or ≥9% when compared to patients who were not hospitalized (Table 3 and Table 4 ). Other factors significantly associated with hospitalization were older age, female sex, higher SES, CVA, and chronic lung disease. In our cohort, obesity and smoking status were not associated with an increased risk for hospitalization. In a multivariate analysis, controlling for multiple prior clinical conditions, the only parameter associated with a significantly increased risk for hospitalization was A1C≥9% (adjusted OR 4.95; 95% CI 1.55-15.76; p<0.05)]. Other variables had no significant impact on the risk for hospitalization due to COVID-19 (Table 5) . We repeated the multivariate analysis with an A1C cutoff of >7% or with A1C as a continuous variable. In the former analysis the OR for hospitalization in patients with an A1C>7% was 6.07 (95%CI 2.36-15.62; p<0.005). Furthermore, an increased risk for hospitalization was observed in patients with prior congestive heart failure and a reduced risk for hospitalization in patients with low SES (Supplementary Table 1 ). In the latter analysis, any increase in A1C by 1% above a 5% baseline was associated with an OR for hospitalization of 1.46 (95% CI 1.14-1.85; p=0.002). In this model, low socioeconomic status was protective and age was a risk factor for hospitalization (Supplementary Table 2 ). This article is protected by copyright. All rights reserved. Using pre-infection glycemic control data we identify A1C as a clear predictor of COVID-19 severity (as assessed by the need for hospitalization). Other clinical characteristics which were significantly linked to hospitalization included female gender, low socioeconomic status, a prior CVA and chronic lung disease. Surprisingly, obesity and smoking status and male sex were not associated with hospitalization despite being suggested as risk factors in prior publications [13] [14] [15] . In a multivariate logistic regression model adjusting for multiple potential risk factors and chronic conditions which may have a deleterious effect on disease outcomes (including age, sex, smoking, IHD, socioeconomic status, depression/anxiety, schizophrenia, dementia, hypertension, CVA, CHF, chronic lung disease and obesity), only A1C≥9% remained a significant predictor for hospitalization. In fact, A1C remained a strong predictor of hospitalization due to COVID-19 when the model was repeated with an A1C cutoff of >7% or when addressing A1C as a continuous variable. Prior studies linking glycemic control and COVID-19 have suggested an association between in hospital glucose levels and disease severity. The link between hyperglycemia during hospitalization and disease severity has been previously reported in numerous studies covering multiple disease conditions [16] [17] [18] . However, tight glycemic control failed to lead to improved outcomes in hospitalized patients in conditions other than COVID-19 [19] . This may suggest that hyperglycemia is a biomarker for the severity of the disease and poor overall health status rather than having an actual causative effect. To our knowledge, our study is the first to identify pre-infection glycemic control as a risk factor for COVID-19 severity. Our study's weaknesses are its relatively small number of hospitalized patients, retrospective design and lack of information regarding disease severity beyond the need for hospitalization. It would be interesting to learn whether A1C predicts COVID-19 mortality, need for ICU stay or need for artificial ventilation. Moreover, our study does not prove that pre-infection glycemic control has a causative role in COVID-19 severity. Similar to hyperglycemia during hospitalization, A1C may be a biomarker of poor health. Future mechanistic studies are needed to determine this relationship. However, the multivariate logistic regression statistical model identifying A1C as the only predictor of COVID-19 hospitalization among numerous other severe and chronic health conditions (including prior cardiovascular disease, mental illness, chronic lung disease etc.) and the observation that risk for hospitalization increases already at A1C≥8% may suggest its pathogenic importance and clinical utility in risk stratification. Other strengths of our study are the large and comprehensive cohort (including all COVID-19 tested patients with diabetes in a large HMO) and the large amount of pre-COVID-19 clinical background information which we could access and present. As many countries continue to battle with the COVID-19 pandemic while others begin to release strict measures of social distancing, identifying high risk populations is key to successfully overcome this disease. Paying special attention to patients with diabetes and an A1C≥9 while allowing a more lenient approach to patients with well controlled disease may prove to be beneficial in minimizing the economic and social burden associated with an undiscriminating approach. Moreover, once a vaccine is available, prioritizing those who are at highest risk for severe COVID-19 will be crucial to efficiently overcome this disease. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. This article is protected by copyright. All rights reserved. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia -A systematic review, meta-analysis, and meta-regression Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome Diabetes is a risk factor for the progression and prognosis of COVID-19 Managing Type 2 Diabetes Mellitus during COVID-19 Pandemic: The Bittersweet Clinical Characteristics of 28 Patients with Diabetes and Covid-19 in Wuhan Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan Admission Hyperglycemia and Radiological findings of SARS-COv2 in patients with and without Diabetes Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes Characterization and Classification of Geographical Units by the Socio-Economic Level of the Population Prevalence of selected chronic diseases in Israel Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 -COVID-NET, 14 States High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview Effects of admission hyperglycemia on mortality and costs in acute ischemic stroke Benefits and risks of tight glucose control in critically ill adults: a meta-analysis This article is protected by copyright. All rights reserved.